Anavex Life Sciences (AVXL) Retained Earnings (2011 - 2025)
Anavex Life Sciences recorded quarterly Retained Earnings of -$388.1 million in Q4 2025, down 1.49% quarter-over-quarter from -$382.4 million in Q3 2025, and down 11.47% year-over-year from -$438.4 million in Q4 2024.
Anavex Life Sciences' Retained Earnings history runs 15 years deep, the most recent figure standing at -$388.1 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 11.47% year-over-year to -$388.1 million; the TTM figure through Dec 2025 stood at -$388.1 million (down 11.47% YoY), while the FY2025 annual figure was -$382.4 million, down 13.8% from the prior year.
- Retained Earnings came in at -$388.1 million for Q4 2025 at Anavex Life Sciences, down from -$382.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$175.7 million in Q1 2021 to a low of -$388.1 million in Q4 2025.
- A 5-year average of -$284.7 million and a median of -$288.0 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings dropped 24.6% in 2022 and dropped 11.47% in 2025, its largest moves.
- Anavex Life Sciences' Retained Earnings stood at -$208.5 million in 2021, then slipped by 24.02% to -$258.5 million in 2022, then fell by 16.69% to -$301.7 million in 2023, then retreated by 15.41% to -$348.2 million in 2024, then declined by 11.47% to -$388.1 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$388.1 million, -$382.4 million, and -$372.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -388.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -388.13 Mn |
| Sep 30, 2025 | -382.45 Mn |
| Jun 30, 2025 | -372.62 Mn |
| Mar 31, 2025 | -359.38 Mn |
| Dec 31, 2024 | -348.18 Mn |
| Sep 30, 2024 | -336.07 Mn |
| Jun 30, 2024 | -324.45 Mn |
| Mar 31, 2024 | -312.24 Mn |
| Dec 31, 2023 | -301.69 Mn |
| Sep 30, 2023 | -293.07 Mn |
| Jun 30, 2023 | -282.92 Mn |
| Mar 31, 2023 | -271.64 Mn |
| Dec 31, 2022 | -258.54 Mn |
| Sep 30, 2022 | -245.56 Mn |
| Jun 30, 2022 | -231.27 Mn |
| Mar 31, 2022 | -218.91 Mn |
| Dec 31, 2021 | -208.47 Mn |
| Sep 30, 2021 | -197.59 Mn |
| Jun 30, 2021 | -185.87 Mn |
| Mar 31, 2021 | -175.69 Mn |
| Dec 31, 2020 | -167.53 Mn |
| Sep 30, 2020 | -159.68 Mn |
| Jun 30, 2020 | -153.71 Mn |
| Mar 31, 2020 | -147.23 Mn |
| Dec 31, 2019 | -139.99 Mn |
| Sep 30, 2019 | -133.40 Mn |
| Jun 30, 2019 | -131.35 Mn |
| Mar 31, 2019 | -124.27 Mn |
| Dec 31, 2018 | -116.27 Mn |
| Sep 30, 2018 | -107.10 Mn |
| Jun 30, 2018 | -103.14 Mn |
| Mar 31, 2018 | -100.29 Mn |
| Dec 31, 2017 | -95.54 Mn |
| Sep 30, 2017 | -91.48 Mn |
| Jun 30, 2017 | -86.32 Mn |
| Sep 30, 2016 | -78.02 Mn |
| Jun 30, 2015 | 59.33 Mn |
| Mar 31, 2015 | 55.08 Mn |
| Dec 31, 2014 | 53.36 Mn |
| Sep 30, 2014 | 52.57 Mn |
| Jun 30, 2014 | 42.87 Mn |
| Mar 31, 2014 | 41.87 Mn |
| Dec 31, 2013 | 40.85 Mn |
| Sep 30, 2013 | 41.20 Mn |
| Jun 30, 2013 | 38.22 Mn |
| Mar 31, 2013 | 38.06 Mn |
| Dec 31, 2012 | 37.96 Mn |
| Sep 30, 2012 | 37.50 Mn |
| Jun 30, 2012 | 36.83 Mn |
| Mar 31, 2012 | 32.28 Mn |
| Sep 30, 2011 | 29.20 Mn |